国内外抗肿瘤药物经济学评价文献计量学研究

doi:10.19803/j.1672-8629.2021.08.08

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 737-742.
DOI: 10.19803/j.1672-8629.2021.08.08

• 新型抗肿瘤药物利用、风险性与经济性研究专栏 • 上一篇下一篇

国内外抗肿瘤药物经济学评价文献计量学研究

曹兆流^1,4, 张玮⁵, 乔洋⁶, 马宇昊², 韩峰^1#, 李歆^1,2,3,*

¹南京医科大学药学院,江苏南京 211166;
²南京医科大学医政学院,江苏南京 211166;
³南京医科大学全球健康中心,江苏南京 211166;
⁴南京市栖霞区医院,江苏南京 210046;
⁵同济大学附属上海市肺科医院,上海 200433;
⁶南京医科大学第一临床医学院,江苏南京 211166

收稿日期:2021-03-24 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*李歆,男,博士,教授·博导,临床药学与药物政策。E-mail:xinli@njmu.edu.cn ^#为共同通信作者。
作者简介:曹兆流,男,在读硕士,主管药师,药物经济学、药事管理、临床药学。
基金资助:
国家自然科学基金资助项目（72074123,716731471）; 江苏省政策引导类计划（软科学研究）（BR2020043）

Bibliometric Analysis of Global Scientific Research on Economic Evaluation of Anticancer Agents

CAO Zhaoliu^1,4, ZHANG Wei⁵, QIAO Yang⁶, MA Yuhao², HAN Feng^1#, LI Xin^1,2,3,*

¹School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 211166, China;
²School of Health Policy and Management, Nanjing Medical University, Nanjing Jiangsu 211166, China;
³Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing Jiangsu 211166, China;
⁴Nanjing Qixia District Hospital, Nanjing 210046, China;
⁵Shanghai Pulmonary Hospital, Shanghai 200433, China;
⁶The First Clinical Medical School, Nanjing Medical University, Nanjing Jiangsu 211166, China

Received:2021-03-24 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 目的对抗肿瘤药物经济学评价研究进行文献计量学分析。方法在Web of Science进行文献检索,检索时间为建库至2020年12月31日,提取相关信息,利用VosViewer软件和Excel对该领域发文量、国家/地区贡献情况、研究机构贡献情况、学者贡献情况、基金赞助情况、研究热点分析等相关内容进行分析。结果共纳入550篇文献。分析显示,该领域总体发表文献数量呈稳步增长趋势,近5年发文量呈现较大幅度增长,我国抗肿瘤药物经济学论文数量在全球呈逐步领先趋势。非小细胞肺癌和新型抗肿瘤药物为近年研究热点。结论抗肿瘤药物经济学评价领域的研究正在伴随着疾病谱的变化、新药研发速度加快等因素在各个国家迅速发展。随着国家医疗保险药品谈判政策的落地,我国的有关研究必将得到进一步发展。

关键词: 抗肿瘤药物, 经济学评价, 文献计量学

Abstract: Objective To conduct bibliometric analysis of pharmacoeconomic evaluation of anticancer agents. Methods Related literature and information were retrieved from Web of Science from inception to December 31, 2020. VosViewer software and Excel were used to analyze the trends relating to the volume of articles published in this field, country/regional contribution, contribution of research institutions, contribution of scholars, funds and hotspots of research. Results A total of 550 articles were included in the analysis. The overall number of published papers in this field continued upwards, especially in the past five years. The number of papers on anti-tumor pharmacoeconomics published in China was gradually leading the world. Drugs for non-small cell lung cancer (NSCLC) and new anticancer agents have become priorities of research in recent years. Conclusion The research on pharmacoeconomic evaluation of anticancer agents is fast-developing globally with the change of disease spectra and the acceleration of new drug research. With the implementation of policies on negotiations about national medical insurance drugs, the related research in China will gain momentum.

Key words: anticancer agents, pharmacoeconomic evaluation, bibliometric

中图分类号:

R956 R-056

曹兆流, 张玮, 乔洋, 马宇昊, 韩峰, 李歆. 国内外抗肿瘤药物经济学评价文献计量学研究[J]. 中国药物警戒, 2021, 18(8): 737-742.

CAO Zhaoliu, ZHANG Wei, QIAO Yang, MA Yuhao, HAN Feng, LI Xin. Bibliometric Analysis of Global Scientific Research on Economic Evaluation of Anticancer Agents[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 737-742.

参考文献

[1] Wilson A, Cohen J.Patient access to new cancer drugs in the United States and Australia[J]. Value in Health, 2011, 14(6): 944-952.
[2] Kantarjian HM, Fojo T, Mathisen M, et al.Cancer drugs in the United States: Justum Pretium—the just price[J]. Journal of Clinical Oncology, 2013, 31(28): 3600.
[3] Robinson JC, Howell S.Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use[J]. Health Affairs, 2014, 33(10): 1745-1750.
[4] Cunningham PJ.The share of people with high medical costs increased prior to implementation of the affordable care act[J]. Health Affairs, 2015, 34(1): 117-124.
[5] Doshi JA, Li P, Pettit AR, et al.Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents[J]. J Clin Oncol, 2018, 36(5): 476-482.
[6] Carrera PM, Kantarjian HM, Blinder VS.The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2): 153-165.
[7] Chen XZ, Jiang K, Hu JK, et al.Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China[J]. World Journal of Gastroenterology, 2008, 14(17):2715-2722.
[8] Crathorne L, Huxley N, Haasova M, et al.The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model[J]. Health Technol Assess, 2016, 20(13): 1-588.
[9] Lazzaro C, Barone C, Caprioni F, et al.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study[J]. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(4): 435-446.
[10] Hirsh V, Singh J.Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness[J]. Am J Health Syst Pharm, 2020, 77(18): 1466-1476.
[11] Maximiano S, Magalhães P, Guerreiro MP, et al.Trastuzumab in the treatment of breast cancer[J]. Bio Drugs, 2016, 30(2): 75-86.
[12] Mármol I, Sánchez-de-Diego C, Pradilla DA, et al. Colore-ctal carcinoma: a general overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1): 197.
[13] Van Cutsem E, Köhne CH, Hitre E, et al.Cetuximab and chemot-herapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417.
[14] Yoneda K, Imanishi N, Ichiki Y, et al.Treatment of non-small cell lung cancer with EGFR-mutations[J]. J Uoeh, 2019, 41(2): 153-163.
[15] Ahn MJ, Sun JM, Lee SH, et al.Egfr tki combination with immunotherapy in non-small cell lung cancer[J]. Expert Opin Drug Saf, 2017, 16(4): 465-469.
[16] HHerbst RS, Garon EB, Kim DW, et al.Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study[J]. Clin Oncol, 2020, 38(14): 1580-1590.

国内外抗肿瘤药物经济学评价文献计量学研究

Bibliometric Analysis of Global Scientific Research on Economic Evaluation of Anticancer Agents

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[2]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[3]	徐帅, 陈恂, 卞昊宇, 赵玉清, 张立平. 基于CiteSpace知识图谱的中草药致肝损伤研究热点与趋势分析[J]. 中国药物警戒, 2023, 20(5): 560-567.
[4]	罗世书, 屈杰, 周楠, 徐翠香, 刘屹, 张丽洁, 王建华. 289例单克隆抗体抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(4): 444-448.
[5]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[6]	邰新娟, 马洪凤, 李君, 马维兴, 闫亚卫. 400例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2022, 19(5): 541-544.
[7]	何璇, 王晓, 戴惠珍, 李歆, 韩峰. 2018年~2020年南京地区新型抗肿瘤药物利用分析[J]. 中国药物警戒, 2021, 18(8): 725-730.
[8]	郑明节, 程蓉, 宋海波. 我国药物警戒研究的文献计量分析[J]. 中国药物警戒, 2021, 18(7): 686-688.
[9]	王雨, 林志健, 姜卓希, 杨婷, 王笑, 张冰. 生物信息技术预警乌头类中药抗乳腺癌用药风险[J]. 中国药物警戒, 2021, 18(7): 655-662.
[10]	蒋慧群, 李歆, 韩峰. 国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性研究[J]. 中国药物警戒, 2021, 18(11): 1075-1079.
[11]	徐银莹, 陆子红, 李琪, 陆牡丹, 姜孙旻. 质子泵抑制剂对口服靶向抗肿瘤药物吸收影响的研究进展[J]. 中国药物警戒, 2021, 18(11): 1091-1096.
[12]	吴红, 李歆, 韩峰. 某三级肿瘤专科医院单克隆抗体类新型抗肿瘤药临床使用合理性与安全性分析[J]. 中国药物警戒, 2021, 18(10): 960-964.
[13]	白顺民, 范哲. 某院静脉药物调配中心抗肿瘤药物不合理用药分析[J]. 中国药物警戒, 2020, 17(4): 239-244.
[14]	韦灵玉, 邱晓春^*, 周彦来, 王作荣. 我院907例抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2017, 14(4): 242-245.
[15]	朱忱崔璨, 李晓玲, 闫素英王育琴. 281例抗肿瘤药物用药错误分析[J]. 中国药物警戒, 2017, 14(1): 40-44.